Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Study sites: 0 to 1
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: details revised at 4 of 7 entries
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to evaluate the efficacy and safety of neoadjuvant trastuzumab rezetecan combined with adebrelimab for the treatment of HER2-positive muscle-invasive bladder cancer.
Trial Details
NCT Number NCT07624201
Lead Sponsor Harbin Medical University
Collaborators: The Fourth Affiliated Hospital of China Medical University, Jilin Provincial Tumor Hospital, Tianjin Medical University Second Hospital, First Hospital of China Medical University
Conditions
(from sponsor)		 Muscle-Invasive Bladder Cancer (MIBC)
Enrollment 58 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov